These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25879386)

  • 1. Genetic determinants of tissue factor pathway inhibitor plasma levels.
    Dennis J; Kassam I; Morange PE; Trégouët DA; Gagnon F
    Thromb Haemost; 2015 Aug; 114(2):245-57. PubMed ID: 25879386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of TFPI polymorphisms rs8176592, rs10931292, and rs10153820 with venous thrombosis: A meta-analysis.
    Zhang Y; Pang A; Zhao L; Guo Q; Zhang Z; Zhu X; Wei R; Yin X; Wang B; Li X
    Medicine (Baltimore); 2019 Mar; 98(12):e14978. PubMed ID: 30896671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
    Dennis J; Truong V; Aïssi D; Medina-Rivera A; Blankenberg S; Germain M; Lemire M; Antounians L; Civelek M; Schnabel R; Wells P; Wilson MD; Morange PE; Trégouët DA; Gagnon F
    J Thromb Haemost; 2016 Oct; 14(10):1960-1970. PubMed ID: 27490645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association study to evaluate TFPI gene in CAD in Han Chinese.
    Zhao Y; Yu Y; Shi M; Yang X; Li X; Jiang F; Chen Y; Tian X
    BMC Cardiovasc Disord; 2017 Jul; 17(1):188. PubMed ID: 28716011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels.
    Dennis J; Medina-Rivera A; Truong V; Antounians L; Zwingerman N; Carrasco G; Strug L; Wells P; Trégouët DA; Morange PE; Wilson MD; Gagnon F
    Genet Epidemiol; 2017 Jul; 41(5):455-466. PubMed ID: 28421636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Asn221Ser mutation in tissue factor pathway inhibitor-beta with plasma total tissue factor pathway inhibitor level.
    Ishikawa J; Okada H; Kato H; Takeshita S; Honda S; Kawasaki T; Suehisa E; Tsuji H; Madoiwa S; Sakata Y; Kojima T; Murata M; Ikeda Y; Kokubo Y; Okamura T; Tomoike H; Miyata T
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):22-6. PubMed ID: 20523161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant genetic association of a functional TFPI variant with circulating fibrinogen levels and coronary artery disease.
    Naji DH; Tan C; Han F; Zhao Y; Wang J; Wang D; Fa J; Li S; Chen S; Chen Q; Xu C; Wang QK
    Mol Genet Genomics; 2018 Feb; 293(1):119-128. PubMed ID: 28894953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of a T-287C polymorphism in the tissue factor pathway inhibitor gene and identification of a repressor element in the promoter.
    Amini Nekoo A; Iles D
    Thromb Res; 2008; 121(6):813-9. PubMed ID: 17931693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in antithrombin and in tissue factor pathway inhibitor genes are associated with recurrent pregnancy loss.
    Guerra-Shinohara EM; Bertinato JF; Tosin Bueno C; Cordeiro da Silva K; Burlacchini de Carvalho MH; Pulcineli Vieira Francisco R; Zugaib M; Cerda A; Morelli VM
    Thromb Haemost; 2012 Oct; 108(4):693-700. PubMed ID: 22918506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A locus on chromosome 2 influences levels of tissue factor pathway inhibitor: results from the GAIT study.
    Almasy L; Soria JM; Souto JC; Warren DM; Buil A; Borrell M; Muñoz X; Sala N; Lathrop M; Fontcuberta J; Blangero J
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1489-92. PubMed ID: 15845911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
    Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
    Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis.
    Dahm A; Van Hylckama Vlieg A; Bendz B; Rosendaal F; Bertina RM; Sandset PM
    Blood; 2003 Jun; 101(11):4387-92. PubMed ID: 12560220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L]TFPI.
    Kleesiek K; Schmidt M; Götting C; Brinkmann T; Prohaska W
    Blood; 1998 Nov; 92(10):3976-7. PubMed ID: 9867356
    [No Abstract]   [Full Text] [Related]  

  • 14. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM; Stendt CL; Vollenhoven BJ; Gan TE; Tipping PG
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis.
    Kleesiek K; Schmidt M; Götting C; Schwenz B; Lange S; Müller-Berghaus G; Brinkmann T; Prohaska W
    Thromb Haemost; 1999 Jul; 82(1):1-5. PubMed ID: 10456444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
    Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
    Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
    Ariëns RA; Alberio G; Moia M; Mannucci PM
    Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
    Opstad TB; Eilertsen AL; Høibraaten E; Skretting G; Sandset PM
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis.
    Amini-Nekoo A; Futers TS; Moia M; Mannucci PM; Grant PJ; Ariëns RA
    Br J Haematol; 2001 May; 113(2):537-43. PubMed ID: 11380428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant.
    Morange PE; Peiretti F; Gourhant L; Proust C; Soukarieh O; Pulcrano-Nicolas AS; Saripella GV; Stefanucci L; Lacroix R; Ibrahim-Kosta M; Lemarié CA; Frontini M; Alessi MC; Trégouët DA; Couturaud F
    PLoS Genet; 2021 Jan; 17(1):e1009284. PubMed ID: 33465109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.